Search research articles
Contact Us
Filters
Showing results (81-90 of 109) with videos related to
Page
of 11
Sort By:
Clinical Pharmacology and Therapeutics
|
November 12, 2019
Transforming Translation Through Quantitative Pharmacology for High-Impact Decision Making in Drug Discovery and Development
Neeraj Gupta, Dean Bottino, Ulrika S H Simonsson, et al.
International Journal of Antimicrobial Agents
|
March 9, 2023
Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects
Simon E Koele, Patrick P J Phillips, Caryn M Upton, et al.
Clinical and Translational Science
|
April 9, 2020
Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug Development
Rob C Van Wijk, Astrid M van der Sar, Elke H J Krekels, et al.
Annals of the American Thoracic Society
|
September 26, 2023
Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept Study
Saskia Janssen, Caryn M Upton, Veronique R De Jager, et al.
Frontiers in Pharmacology
|
March 31, 2023
Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
Rami Ayoun Alsoud, Robin J Svensson, Elin M Svensson, et al.
The Journal of Infectious Diseases
|
February 19, 2021
Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
Saskia E Mudde, Rami Ayoun Alsoud, Aart van der Meijden, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
July 31, 2021
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
Mike Marvin Ruth, Jelmer Raaijmakers, Erik van den Hombergh, et al.
BMJ Open
|
March 11, 2022
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
David Ekqvist, Anna Bornefall, Daniel Augustinsson, et al.
The Journal of Antimicrobial Chemotherapy
|
February 4, 2014
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses
Simbarashe P Zvada, Paolo Denti, Peter R Donald, et al.
Antimicrobial Agents and Chemotherapy
|
November 6, 2013
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients
Simbarashe P Zvada, Paolo Denti, Frederick A Sirgel, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 109) with videos related to
Sort By:
Page
of 11
Clinical Pharmacology and Therapeutics
|
November 12, 2019
Transforming Translation Through Quantitative Pharmacology for High-Impact Decision Making in Drug Discovery and Development
Neeraj Gupta, Dean Bottino, Ulrika S H Simonsson, et al.
International Journal of Antimicrobial Agents
|
March 9, 2023
Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects
Simon E Koele, Patrick P J Phillips, Caryn M Upton, et al.
Clinical and Translational Science
|
April 9, 2020
Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug Development
Rob C Van Wijk, Astrid M van der Sar, Elke H J Krekels, et al.
Annals of the American Thoracic Society
|
September 26, 2023
Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept Study
Saskia Janssen, Caryn M Upton, Veronique R De Jager, et al.
Frontiers in Pharmacology
|
March 31, 2023
Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
Rami Ayoun Alsoud, Robin J Svensson, Elin M Svensson, et al.
The Journal of Infectious Diseases
|
February 19, 2021
Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
Saskia E Mudde, Rami Ayoun Alsoud, Aart van der Meijden, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
July 31, 2021
Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
Mike Marvin Ruth, Jelmer Raaijmakers, Erik van den Hombergh, et al.
BMJ Open
|
March 11, 2022
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
David Ekqvist, Anna Bornefall, Daniel Augustinsson, et al.
The Journal of Antimicrobial Chemotherapy
|
February 4, 2014
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses
Simbarashe P Zvada, Paolo Denti, Peter R Donald, et al.
Antimicrobial Agents and Chemotherapy
|
November 6, 2013
Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients
Simbarashe P Zvada, Paolo Denti, Frederick A Sirgel, et al.
Page
of 11